Cargando…
Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has thrown a challenge to the scientific community. Several interventions to stop or limit the spread of infection have failed, and every time the virus emerges, it becomes more contagious and more deadly. Vaccinating a significant proport...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850041/ https://www.ncbi.nlm.nih.gov/pubmed/35186175 http://dx.doi.org/10.1155/2022/6913772 |
_version_ | 1784652525897515008 |
---|---|
author | Basheeruddin Asdaq, Syed Mohammed Jomah, Shahamah Rabbani, Syed Imam Alamri, Ali Musharraf Salem Alshammari, Salman Khalaf Duwaidi, Badr Sami Alshammari, Majed Sadun Alamri, Abdulhakeem S. Alsanie, Walaa F. Alhomrani, Majid Sreeharsha, Nagaraja Imran, Mohd. |
author_facet | Basheeruddin Asdaq, Syed Mohammed Jomah, Shahamah Rabbani, Syed Imam Alamri, Ali Musharraf Salem Alshammari, Salman Khalaf Duwaidi, Badr Sami Alshammari, Majed Sadun Alamri, Abdulhakeem S. Alsanie, Walaa F. Alhomrani, Majid Sreeharsha, Nagaraja Imran, Mohd. |
author_sort | Basheeruddin Asdaq, Syed Mohammed |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has thrown a challenge to the scientific community. Several interventions to stop or limit the spread of infection have failed, and every time the virus emerges, it becomes more contagious and more deadly. Vaccinating a significant proportion of the population is one of the established methods to achieve herd immunity. More than 100 COVID-19 vaccines have been designed and tested against the virus. The development of a new vaccine takes years of testing, but due to the pandemic, healthcare authorities have given emergency use authorization for a few vaccines. Among them are BioNTech and Moderna vaccines (mRNA based); ChAdOx1, Gam-COVID-Vac, Janssen vaccines (vector-based); CoronaVac, COVAXIN (virus inactivated); and EpiVacCorona vaccine (viral peptide). Mixtures of vaccines are also being tested to evaluate their efficacy against mutant strains of SARS-CoV-2. All these vaccines in clinical trials have shown robust production of neutralizing antibodies sufficient to prevent infection. Some of the vaccinated people reported serious complications. However, no definitive relationship could be established between vaccination administration and the occurrence of these complications. None of the COVID-19 vaccines approved to date have been found to be effective against all of the SARS-CoV-2 variants. |
format | Online Article Text |
id | pubmed-8850041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-88500412022-02-17 Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines Basheeruddin Asdaq, Syed Mohammed Jomah, Shahamah Rabbani, Syed Imam Alamri, Ali Musharraf Salem Alshammari, Salman Khalaf Duwaidi, Badr Sami Alshammari, Majed Sadun Alamri, Abdulhakeem S. Alsanie, Walaa F. Alhomrani, Majid Sreeharsha, Nagaraja Imran, Mohd. Can J Infect Dis Med Microbiol Review Article Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has thrown a challenge to the scientific community. Several interventions to stop or limit the spread of infection have failed, and every time the virus emerges, it becomes more contagious and more deadly. Vaccinating a significant proportion of the population is one of the established methods to achieve herd immunity. More than 100 COVID-19 vaccines have been designed and tested against the virus. The development of a new vaccine takes years of testing, but due to the pandemic, healthcare authorities have given emergency use authorization for a few vaccines. Among them are BioNTech and Moderna vaccines (mRNA based); ChAdOx1, Gam-COVID-Vac, Janssen vaccines (vector-based); CoronaVac, COVAXIN (virus inactivated); and EpiVacCorona vaccine (viral peptide). Mixtures of vaccines are also being tested to evaluate their efficacy against mutant strains of SARS-CoV-2. All these vaccines in clinical trials have shown robust production of neutralizing antibodies sufficient to prevent infection. Some of the vaccinated people reported serious complications. However, no definitive relationship could be established between vaccination administration and the occurrence of these complications. None of the COVID-19 vaccines approved to date have been found to be effective against all of the SARS-CoV-2 variants. Hindawi 2022-02-09 /pmc/articles/PMC8850041/ /pubmed/35186175 http://dx.doi.org/10.1155/2022/6913772 Text en Copyright © 2022 Syed Mohammed Basheeruddin Asdaq et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Basheeruddin Asdaq, Syed Mohammed Jomah, Shahamah Rabbani, Syed Imam Alamri, Ali Musharraf Salem Alshammari, Salman Khalaf Duwaidi, Badr Sami Alshammari, Majed Sadun Alamri, Abdulhakeem S. Alsanie, Walaa F. Alhomrani, Majid Sreeharsha, Nagaraja Imran, Mohd. Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines |
title | Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines |
title_full | Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines |
title_fullStr | Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines |
title_full_unstemmed | Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines |
title_short | Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines |
title_sort | insight into the advances in clinical trials of sars-cov-2 vaccines |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850041/ https://www.ncbi.nlm.nih.gov/pubmed/35186175 http://dx.doi.org/10.1155/2022/6913772 |
work_keys_str_mv | AT basheeruddinasdaqsyedmohammed insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT jomahshahamah insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT rabbanisyedimam insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT alamrialimusharraf insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT salemalshammarisalmankhalaf insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT duwaidibadrsami insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT alshammarimajedsadun insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT alamriabdulhakeems insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT alsaniewalaaf insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT alhomranimajid insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT sreeharshanagaraja insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT imranmohd insightintotheadvancesinclinicaltrialsofsarscov2vaccines |